Duodenal α-Synuclein PFF Injection Induces Vagus-Related Gut-to-Brain Pathology in C57BL/6J and A53T Transgenic Mice.
Level 5 - mechanism / opinion, no new human data
Animal model study (preclinical research)
PubMed 42651119 · doi:10.3390/brainsci16080804
What was done
Investigators injected alpha-synuclein preformed fibrils into the duodenal muscularis of C57BL/6J wild-type and A53T transgenic mice to model gut-originating Parkinson's disease. They evaluated phosphorylated alpha-synuclein accumulation, motor behavior, and gut microbiota composition, while also testing the effect of truncal vagotomy on gut-to-brain pathological spread.
What was found
The abstract reports no numerical metrics or statistical values. In C57BL/6J mice at four months post-injection, phosphorylated alpha-synuclein deposition was detected in the duodenal muscularis and striatum, alongside gut microbiota alterations and motor behavioral deficits. Truncal vagotomy was associated with reduced brain phosphorylated alpha-synuclein levels and altered gut microbiota. A53T transgenic mice also developed phosphorylated alpha-synuclein pathology and neurodegenerative changes following fibril injection.
Why it matters
The study provides experimental support for the Braak hypothesis, indicating that duodenal alpha-synuclein pathology can propagate to the central nervous system via vagal pathways to drive Parkinsonian features.
Limits
Findings derive solely from mouse models and cannot establish human clinical causality. The abstract omits sample sizes, quantitative effect estimates, and statistical confidence bounds. Furthermore, the A53T transgenic arm lacked genetically matched wild-type controls, precluding definitive attribution of the phenotype specifically to the A53T genotype.
Cited by
- supports In Parkinson's disease, alpha-synuclein pathology can propagate physically from the gut to the brain via the vagus nerve.